Zepbound
-
Eli Lilly Breaks Out with Zepbound, Hits Trillion-Dollar Valuation
Eli Lilly had a breakout year in 2025, largely thanks to its new obesity treatment Zepbound. Alongside its diabetes-focused medication Mounjaro, Lilly’s products outsold all other pharmaceuticals in the first three quarters. The company’s strong sales performance helped it become the first drugmaker to hit a trillion-dollar valuation. Novo Nordisk Racing to Close the Gap…
